Metropolis Healt

Who are the top shareholders of the Metropolis Healt?

The top shareholders of Metropolis Health include Metz Advisory LLP with 30.29%, mutual funds holding 26.42% (led by HDFC Mutual Fund at 9.64%), foreign institutional investors at 15.29%, and individual investors at 3.84%.

The top shareholders of Metropolis Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Metz Advisory LLP holding the highest stake at 30.29%. Mutual funds collectively hold 26.42% of the company, with HDFC Mutual Fund - HDFC Focused 30 Fund being the largest public shareholder at 9.64%. Additionally, FIIs own 15.29% of the shares, while individual investors hold 3.84%.

how big is Metropolis Healt?

As of Jun 06, Metropolis Healthcare Ltd has a market capitalization of 8,629.00 Cr, with recent net sales of 1,331.21 Cr and a net profit of 144.97 Cr for the latest four quarters. Shareholder's funds are valued at 1,096.16 Cr, and total assets amount to 1,547.43 Cr as of Mar'24.

Market Cap: As of Jun 06, Metropolis Healthcare Ltd has a market capitalization of 8,629.00 Cr, which classifies it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the company reported a sum of Net Sales of 1,331.21 Cr and a sum of Net Profit of 144.97 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 1,096.16 Cr, and the Total Assets amount to 1,547.43 Cr.

Has Metropolis Healt declared dividend?

Metropolis Healthcare Ltd has declared a 200% dividend, amounting to ₹4 per share, with an ex-date of November 17, 2023. Despite this declaration, the dividend yield is 0%, and recent total returns have been mixed, showing negative performance in the short term and more favorable results over longer periods.

Metropolis Healthcare Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4<BR>- Ex-date: 17 Nov 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.5%, with no dividend return, resulting in a total return of -22.5%.<BR><BR>Over the past year, the price return was -18.18%, with no dividend return, leading to a total return of -18.18%.<BR><BR>In the 2-year period, the price return was 26.39%, with a dividend return of 0.29%, resulting in a total return of 26.68%.<BR><BR>For the 3-year period, the price return was 3.34%, with a dividend return of 0.86%, culminating in a total return of 4.2%.<BR><BR>In the last 4 years, the price return was -34.24%, with a dividend return of 0.71%, leading to a total return of -33.53%.<BR><BR>Over the past 5 years, the price return was 14.39%, with a dividend return of 2.07%, resulting in a total return of 16.46%.<BR><BR>Overall, while Metropolis Healthcare Ltd has declared a significant dividend, the total returns over the recent periods show a mixed performance, with negative returns in the shorter terms and more favorable returns over longer periods. The dividend yield remains at 0%, indicating that the declared dividend has not yet positively impacted the yield for investors.

Who are the peers of the Metropolis Healt?

Metropolis Healt's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Thyrocare Tech., Suven Life Scie., Vimta Labs, Laxmi Dental, and Krsnaa Diagnost. Metropolis Healt has a 1-year return of -11.47%, lower than Syngene Intl.'s -3.47%, with varying management and growth risks among its peers.

Peers: The peers of Metropolis Healt are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Thyrocare Tech., Suven Life Scie., Vimta Labs, Laxmi Dental, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest. Below Average management risk is present at Suven Life Scie. and Krsnaa Diagnost. Growth is Excellent at Laxmi Dental, Good at Vimta Labs, and Average at Poly Medicure, Indegene, and the rest. Below Average growth is noted at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 161.32%, while the lowest is Syngene Intl. at -3.47%. Metropolis Healt's 1-year return is -11.47%, which is lower than Syngene Intl. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., and Krsnaa Diagnost.

Who are in the management team of Metropolis Healt?

As of March 2023, the management team of Metropolis Health includes Sushil Kanubhai Shah (Chairman & Executive Director), Ameera Sushil Shah (Managing Director), and several independent directors, along with a non-executive director and a company secretary, ensuring a diverse governance structure.

As of March 2023, the management team of Metropolis Healt includes the following individuals:<BR><BR>1. Sushil Kanubhai Shah - Chairman & Executive Director<BR>2. Ameera Sushil Shah - Managing Director<BR>3. Vivek Gambhir - Independent Director<BR>4. Sanjay Bhatnagar - Independent Director<BR>5. Milind Shripad Sarwate - Independent Director<BR>6. Anita Ramachandran - Independent Director<BR>7. Hemant Sachdev - Non-Executive & Non-Independent Director<BR>8. Neha Shah - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive, independent, and non-executive members, reflecting a diverse governance structure.

What does Metropolis Healt do?

Metropolis Healthcare Ltd is a mid-cap company in the healthcare services industry, reporting net sales of ₹3,453 Cr and a net profit of ₹291 Cr for Q1 2025. Key metrics include a P/E ratio of 71.00 and a market cap of ₹10,130 Cr.

Overview:<BR>Metropolis Healthcare Ltd operates in the healthcare services industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was established in January 1980 as a partnership firm and has undergone several changes in partnership structure. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3,453 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 291 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 10,130 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 71.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.06 <BR>Return on Equity: 10.89% <BR>Price to Book: 7.28 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

When is the next results date for Metropolis Healt?

Metropolis Health will announce its results on August 7, 2025.

Metropolis Healt will declare its results on 07 August 2025.

Is Metropolis Healt overvalued or undervalued?

As of September 8, 2025, Metropolis Health is considered overvalued with a valuation grade of expensive, reflected by a high PE ratio of 73.15, an EV to EBITDA ratio of 35.71, and a PEG ratio of 7.47, despite outperforming the Sensex over three years.

As of 8 September 2025, the valuation grade for Metropolis Health has moved from very expensive to expensive, indicating a slight easing in perceived overvaluation. The company is currently considered overvalued based on its high valuation metrics, including a PE ratio of 73.15, an EV to EBITDA ratio of 35.71, and a PEG ratio of 7.47. <BR><BR>In comparison to its peers, Metropolis Health's PE ratio is notably higher than Apollo Hospitals at 71.12 and Narayana Hrudaya at 46.06, both of which are also categorized as expensive. The company's recent stock performance has shown a 1-week decline of 0.79%, contrasting with a 0.53% gain in the Sensex, although it has outperformed the index over a 3-year period with a return of 45.26% compared to the Sensex's 35.35%. Overall, Metropolis Health appears to be overvalued in the current market environment.

How has been the historical performance of Metropolis Healt?

Metropolis Healt has shown consistent growth in net sales and profitability, with net sales increasing from 761.18 Cr in March 2019 to 1,331.20 Cr in March 2025, and profit after tax reaching 145.51 Cr in the same period. The company's total assets and liabilities have also significantly grown, reflecting a robust financial performance.

Answer:<BR>The historical performance of Metropolis Healt shows a consistent growth in net sales and profitability over the years, with a notable increase in the most recent fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Metropolis Healt's net sales have risen from 761.18 Cr in March 2019 to 1,331.20 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, reaching 1,331.20 Cr in March 2025, up from 761.18 Cr in March 2019. The company's total expenditure has also increased, amounting to 1,028.21 Cr in March 2025, compared to 560.81 Cr in March 2019. Operating profit, excluding other income, has shown fluctuations but reached 302.99 Cr in March 2025, while profit before tax was recorded at 190.85 Cr. The profit after tax for March 2025 was 145.51 Cr, indicating a steady profitability despite some variations in previous years. The company's total assets have grown significantly from 738.33 Cr in March 2020 to 1,859.09 Cr in March 2025, while total liabilities increased from 738.33 Cr to 1,859.09 Cr in the same period. Cash flow from operating activities has remained relatively stable, with 262.00 Cr in March 2025, although the net cash outflow was recorded at -23.00 Cr. Overall, Metropolis Healt has demonstrated a robust growth pattern in revenue and profitability, alongside an increase in assets and liabilities over the years.

Is Metropolis Healt technically bullish or bearish?

As of December 4, 2025, Metropolis Health's technical trend is neutral with mixed signals, showing a mildly bearish outlook on weekly and monthly Bollinger Bands, while daily moving averages indicate a slight bullish trend, reflecting overall lack of strong momentum.

As of 4 December 2025, the technical trend for Metropolis Healt has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are both mildly bearish, while the monthly MACD remains bullish. The Bollinger Bands indicate a bearish outlook on both weekly and monthly charts. Daily moving averages show a mildly bullish trend, but the overall indicators suggest a lack of strong momentum. The Dow Theory reflects a mildly bearish sentiment on the weekly chart and bullish on the monthly. Given the recent price action, including a decline from the previous close, the technical stance remains neutral with a slight bearish inclination in the short term.

Are Metropolis Healthcare Ltd latest results good or bad?

Metropolis Healthcare Ltd's Q2 FY26 results are generally positive, with a net profit increase of 13.22% and revenue growth of 22.70%. However, slight declines in operating margins and high stock valuation may raise investor caution despite the strong growth.

Metropolis Healthcare Ltd's latest results for Q2 FY26 can be characterized as generally positive, particularly in terms of revenue and profit growth. The company reported a net profit of ₹52.67 crores, which reflects a year-on-year increase of 13.22% and a sequential improvement of 16.89%. Additionally, revenue reached ₹429.19 crores, showing a robust year-on-year growth of 22.70% and an 11.17% increase compared to the previous quarter.<BR><BR>However, there are some concerns regarding operating margins. The operating margin decreased slightly by 48 basis points year-on-year to 25.22%, although it did improve sequentially from the previous quarter. The profit after tax (PAT) margin also saw a decline compared to the same quarter last year, although it was up from the previous quarter.<BR><BR>Overall, while the company has demonstrated strong revenue growth and profit increases, the slight margin pressures and the market's muted reaction to the results suggest that investors may be cautious. The stock trades at a high valuation, which could limit upside potential unless the company can sustain its growth momentum. Thus, while the results are good in terms of growth, the valuation and margin pressures present some challenges.

Should I buy, sell or hold Metropolis Healthcare Ltd?

What is the bonus history of Metropolis Healt?

Metropolis Healthcare Ltd recently announced a 3:1 bonus issue, with an ex-date of March 20, 2026, meaning shareholders will receive three additional shares for every one share held.

Metropolis Healthcare Ltd has a recent bonus issue where they announced a 3:1 bonus. The ex-date for this bonus is set for March 20, 2026. This means that for every one share held, shareholders will receive three additional shares. If you have any further questions about the company or its financial actions, feel free to ask!

Why is Metropolis Healthcare Ltd falling/rising?

As of 03-Apr, Metropolis Healthcare Ltd's stock price is declining, currently at 422.95, reflecting a downward trend and reduced investor participation. Concerns over long-term growth and high valuation metrics further contribute to the stock's falling price.

As of 03-Apr, Metropolis Healthcare Ltd's stock price is falling, currently at 422.95, which reflects a change of -0.85 (-0.2%). The stock has been on a downward trend, having lost -2.4% over the last two days and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This indicates a consistent decline in price momentum.<BR><BR>Additionally, there has been a significant drop in investor participation, with delivery volume on April 1 falling by 71.5% compared to the 5-day average. This reduced trading activity suggests a lack of interest from investors, which can contribute to downward pressure on the stock price.<BR><BR>While the company has shown some positive financial metrics, such as a high return on equity (ROE) of 16.21% and strong growth in net sales and profit after tax over the last six months, these factors are overshadowed by concerns regarding long-term growth. The stock has demonstrated poor long-term growth rates, with net sales increasing at an annual rate of only 11.40% over the past five years. Furthermore, the stock is considered expensive with a price-to-book value of 6.1, which is higher than its peers, and a PEG ratio of 3.7, indicating that its valuation may not be justified by its earnings growth.<BR><BR>In summary, the combination of declining price momentum, reduced investor participation, and concerns over long-term growth prospects are contributing to the falling stock price of Metropolis Healthcare Ltd.

Why is Metropolis Healthcare Ltd falling/rising?

As of 04-Apr, Metropolis Healthcare Ltd's stock price is declining, currently at 422.95, and has underperformed the market with significant drops in investor participation. The stock is trading below key moving averages and is considered expensive, raising concerns about its long-term growth prospects.

As of 04-Apr, Metropolis Healthcare Ltd's stock price is falling, currently at 422.95, reflecting a change of -0.85 (-0.2%). The stock has been experiencing a decline, having lost -2.4% over the last two days and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>In terms of performance relative to the market, the stock has underperformed over the past week and month, with declines of -3.49% and -9.13%, respectively, compared to the Sensex's -2.60% and -8.62%. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 71.5% against the 5-day average, suggesting reduced interest from investors.<BR><BR>Despite some positive factors, such as high management efficiency and strong recent financial results, the long-term growth outlook appears poor. The company's net sales have only grown at an annual rate of 11.40% over the last five years, and its operating profit growth has been even lower at 3.16%. Furthermore, the stock is considered expensive, trading at a premium with a Price to Book Value of 6.1, and a PEG ratio of 3.7, indicating that its valuation may not be justified by its earnings growth.<BR><BR>Overall, the combination of declining stock performance, reduced investor participation, and concerns over long-term growth prospects contribute to the current downward trend in Metropolis Healthcare Ltd's stock price.

Why is Metropolis Healthcare Ltd falling/rising?

As of 05-Apr, Metropolis Healthcare Ltd's stock price is at 422.95, reflecting a downward trend with a -2.4% loss over the last two days. The stock has underperformed compared to the Sensex and shows weak investor sentiment, with declining participation and a bearish outlook despite some positive financial metrics.

As of 05-Apr, Metropolis Healthcare Ltd's stock price is falling, currently at 422.95, reflecting a change of -0.85 (-0.2%). The stock has been on a downward trend, having lost -2.4% over the last two days and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a weak performance relative to its recent price history.<BR><BR>In the past week, the stock has decreased by -3.49%, which is worse than the Sensex's decline of -2.60%. Over the last month, Metropolis Healthcare has seen a significant drop of -9.13%, compared to the Sensex's -8.62%. Year-to-date, the stock is down -12.30%, while the Sensex has decreased by -13.96%. Despite a positive performance over the last year, with a return of +9.42% compared to the Sensex's -4.30%, the recent trends suggest a deterioration in investor sentiment.<BR><BR>Additionally, there has been a notable decline in investor participation, with delivery volume falling by -71.5% against the 5-day average, which indicates reduced interest in trading the stock. The liquidity remains adequate for trading, but the overall market conditions and the stock's performance metrics suggest a bearish outlook.<BR><BR>While there are some positive factors, such as high management efficiency and strong recent financial results, the long-term growth prospects appear poor, with net sales growing at an annual rate of only 11.40% over the last five years. The stock's valuation is also considered expensive relative to its peers, contributing to the negative sentiment surrounding it.

Which are the latest news on Metropolis Healt?